[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
May 2006

Phototesting in Patients With Smith-Lemli-Opitz Syndrome Confirms Sensitivity to UV-A

Arch Dermatol. 2006;142(5):647-651. doi:10.1001/archderm.142.5.647

Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive disorder of cholesterol metabolism first described in 1964.1 Patients with SLOS are deficient in 7-dehydrocholesterol reductase (DHCR7), the enzyme that catalyzes the final step of the cholesterol biosynthetic pathway, owing to disease-causing mutations in the DHCR7 gene located on chromosome 11q12.13. Deficiency in DHCR7 results in accumulation of cholesterol precursors, in particular, 7-dehydrocholesterol (7-DHC), and low levels of serum cholesterol. Clinical features are variable but include multiple malformations and developmental delay. Photosensitivity is now also a recognized feature, affecting about two thirds of patients with SLOS,2,3 with the action spectrum defined in 3 cases as falling in the UV-A range.3 Treatment for SLOS often includes a diet that is high in cholesterol, which parents of patients with SLOS report is of benefit for the photosensitivity.2,3

First Page Preview View Large
First page PDF preview
First page PDF preview
×